Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514375 | 1.00 | BRD4 (0.48) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL21265754 | 0.90 | EHMT2 (0.43) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL21265776 | 0.88 | BRD4 (0.40) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL21265777 | 0.88 | BRD4 (0.40) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL30514372 | 0.88 | BRD4 (0.40) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL25887858 | 0.86 | EHMT2 (0.47) | STING1CYP2C9EHMT2ABCC4USP2 | |
| SCHEMBL30514364 | 0.85 | PPARG (0.42) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL25887908 | 0.85 | PPARG (0.42) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL21265742 | 0.85 | EHMT2 (0.46) | BRD4STING1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL25887818 | 0.85 | EHMT2 (0.41) | BRD4STING1CYP2C9EHMT2ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. | 2021-07-08 | — | — | US | disclosed |
| WO-2019157338-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712435-B2 | Mebendazole prodrugs with enhanced solubility and oral bioavailability | CYP3A43, CYP3A4, CYP4B1 | BRD4 1452/4885STING1 3992/4885CYP2C9 23/4885 |
| US-20210205271-A1 | MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY | CYP3A43, CYP3A4, CYP4B1 | BRD4 1452/4885STING1 3992/4885CYP2C9 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.